SUBSCRIBE
SUBSCRIBE
News   Drug Development

Iroko Pharmaceuticals Reports Encouraging Results from Study of Naproxen Formulated Using a Proprietary, Patented, Nanotechnology Platform

January 6, 2011 | 
1 min read

(BUSINESS WIRE)--Iroko Pharmaceuticals, LLC today reported the results of the Phase I clinical study of its unique formulation of naproxen, a widely used pain medication, using proprietary, patent protected nanotechnology.

Clinical research Phase I
MORE ON THIS TOPIC
Deviation from the plan, path or norms. Choosing an alternative way, changing the plans and flexibility.
Depression
Neumora Shakes Up Phase III MDD Trials After January Miss
March 3, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Glitter Vibrant Spheres Abstract Background Digital Renderingv
Phase III
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial
March 3, 2025
 · 
2 min read
 · 
Annalee Armstrong
Pop art Medicine pill or tablet icon isolated on color background. Capsule pill and drug sign. Pharmacy design. Vector Illustration
Pain
Lexicon to Advance Non-Opioid Painkiller Despite Mid-Stage Trial Failure
March 3, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Beautiful colorful unpeeled peanut pattern on a light blue background. Flat lay arrangement, top view.
Immunology and inflammation
First Head-to-Head Study Cements Roche’s Xolair as Food Allergy Leader
March 3, 2025
 · 
2 min read
 · 
Tristan Manalac